Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society Annual Meeting
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii To The Cambodian Government At The Joint Review Committee
Blue Jay Gold Announces Materials Purchase Agreement With Ocean Partners for Remediation Material at Steller
SAGA Metals Completes Diamond Drill Program at the Wolverine Rare Earth Project - All 22 Holes Totalling 3,241 Metres Intersect Prospective REE-Bearing Alteration
